Camurus

665.00 SEK

+4.15 %

Less than 1K followers

CAMX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+4.15 %

+7.95 %

+11.30 %

-4.45 %

-0.60 %

+11.20 %

+178.01 %

+264.58 %

+1,000.52 %

Camurus operates in biotechnology. The company is operated as a research-based pharmaceutical company that develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders and patients with opioid addiction. Camurus runs development projects under its own management and in partnership with international pharmaceutical companies. The company is headquartered in Lund.

Market cap

39.82B SEK

Turnover

138.26M SEK

Revenue

1.87B

EBIT %

25.12 %

P/E

89.99

Dividend yield-%

-

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12/2

2026

Annual report '25

12/5

2026

Interim report Q1'26

28/5

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release10 hours ago

Camurus AB: Camurus ansökan om marknadsgodkännande av Oclaiz™ för behandling av akromegali accepterad för granskning av FDA

Regulatory press release10 hours ago

Camurus AB: Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

Regulatory press release12/30/2025, 6:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/30/2025, 6:00 AM

Camurus AB: Förändring av antalet aktier och röster i Camurus

Press release12/16/2025, 10:30 AM

Camurus AB: Camurus och Gubra ingår samarbets- och licensavtal för utveckling av långtidsverkande behandling för hypoparatyreoidism

Press release12/16/2025, 10:30 AM

Camurus AB: Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism

Regulatory press release11/28/2025, 6:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Regulatory press release11/28/2025, 6:00 AM

Camurus AB: Förändring av antalet aktier och röster i Camurus

Regulatory press release11/13/2025, 6:00 AM

Camurus AB: Valberedning utsedd inför Camurus årsstämma 2026

Regulatory press release11/13/2025, 6:00 AM

Camurus AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2026

Press release11/12/2025, 10:41 AM

BioStock: Starka fas Ib-resultat lyfter Camurus i det globala GLP-1-racet

Press release11/12/2025, 9:00 AM

Camurus AB: Camurus presenterar vid Jefferies London Healthcare Conference

Press release11/12/2025, 9:00 AM

Camurus AB: Camurus to present at Jefferies London Healthcare Conference

Regulatory press release11/10/2025, 7:00 AM

Camurus AB: Camurus rapporterar positiva resultat för CAM2056, semaglutid månadsdepå

Regulatory press release11/10/2025, 7:00 AM

Camurus AB: Camurus reports positive topline results for CAM2056, semaglutide monthly depot

Camurus, Audiocast, Q3'25

Webcast11/6/2025, 1:00 PM

Camurus, Audiocast, Q3'25

Regulatory press release11/6/2025, 6:00 AM

Camurus AB: Camurus' Interim Report Third Quarter 2025

Regulatory press release11/6/2025, 6:00 AM

Camurus AB: Camurus delårsrapport tredje kvartalet 2025

Press release11/3/2025, 7:00 AM

Camurus AB: Camurus launches long-acting Oczyesa® for the treatment of acromegaly

Press release11/3/2025, 7:00 AM

Camurus AB: Camurus lanserar långtidsverkande Oczyesa® för behandling av akromegali

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.